Novavax reported results on March 11 from its clinical phase 3 trials of its (NVX-CoV2373) vaccine, showing 96% efficacy in the U.S. for mild, moderate or severe cases of Covid-19. Also, in the UK, in a trial with 15,000 people, only five cases of severe Covid-19 occurred - all of them from the 7,500 people who got placebos. Efficacy there was 86%.
Novavax, a U.S. company, is contracted for 100 million doses for the U.S., and has also committed to deliver 1.1 billion doses to COVAX. They have manufacturing partners in India, Spain, UK, Korea and Japan. They are studying an updated bivalent vaccine, one that could also cover the South African variant.
